Uncovering CNS assess of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet microscopy

Authors

Aleksandra Parka¹, Grethe Skovbjerg¹, Urmas Roostalu¹, Casper Salinas¹, Johanna Perens¹, Jacob L. Skytte¹, Christoffer Clemmensen², Lisbeth Elster¹, Henrik H. Hansen¹ and Jacob Hecksher-Sørensen¹

¹ Gubra, Hørsholm Kongevej 11B, Hørsholm, Denmark ² Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark

Corresponding author

Jacob Hecksher-Sørensen, jhs@gubra.dk

Background & Aim

Peptide-based drug development for CNS disorders is challenged by poor blood-brain barrier (BBB) penetrability of peptides. While acylation protractions (lipidation) have been successfully applied to increase circulating half-life of therapeutic peptides, little is known about the CNS accessibility of lipidated peptide drugs. Lightsheet fluorescence microscopy (LSFM) has emerged as a powerful method to visualize wholebrain 3D distribution of fluorescently labelled therapeutic peptides at single-cell resolution.

Methods

Functional assay

High throughput time-resolved fluorescence cAMP kit was used to measure intracellular cyclic adenosine monophosphate (cAMP) upon incubation of hGLP1-1R CHO-K1 cells with the IR800-labelled peptides.

In vivo experiments

Mice received an intravenous dose of IR800labelled Ex4, Ex4_C16MA or Ex4_C18DA. One group was dosed with Ex9-39_C16MA, serving as negative control for GLP-1R mediated agonist internalization. For 3D biodistribution study, mice were terminated 120 min post-dosing, while for the functional assays, blood glucose and plasma insulin levels at 15 min and 120 min post-dosing.

3D imaging and image analysis

Brains were cleared using the iDISCO+ protocol and imaged using light sheet microscopy (LSFM). Region delineation of the whole-brain samples were obtained by atlas segmentation. Group averages and standard deviations were calculated for each voxel, resulting in p-value calculations compared to the vehicle group.



www.gubra.dk



In vivo distribution of Ex4 peptides in the CNS



Group	Number of animals	Treatment	Administration route	Dosing concentration
Ex4 ⁸⁰⁰	5	Ex4 ⁸⁰⁰	IV	100 nmol/kg
Ex4_C16MA ⁸⁰⁰	5	Ex4_C16MA ⁸⁰⁰	IV	100 nmol/kg
Ex4_C18DA ⁸⁰⁰	5	Ex4_C18DA ⁸⁰⁰	IV	100 nmol/kg
x9-39_C16MA ⁸⁰⁰	5	Ex9-39_C16MA ⁸⁰⁰	IV	100 nmol/kg

Voxel wise statistical maps of Ex4 distribution

Figure 3. In vivo distribution of the fluorescent peptides in CNS. (A) In the CNS there was

pronounced signal intensity in and around the circumventricular organs, choroid plexus and in deeper brain regions such as the PVH, VMH and DMH. (C) Using the individual maps from each mouse (n=6 per group) it is possible to generate voxel based statistical maps. The maps show voxels the are statistical different from the vehicle



Figure 5. Accumulated signal intensities in selected brain regions. In most of the brain regions the C18DA lipidation lead to increased signal intensity. However, in the PVH the C16MA displayed a stronger signal than the C18DA.



In vivo efficacy of Ex4 peptides on BG and plasma insulin





(B) All agonistic peptides lowered blood glucose and lead to increased **(C)** insulin levels. The Ex9-39 antagonistic peptide resulted in increased blood glucose and low blood insulin.

Conclusion

- We have developed a high-throughput 3D imaging deep pipeline for brain-wide analysis of drug distribution
- Using voxel based statistical maps we were able to detect differences in brain distribution of similar peptides
- Our pipeline can be used to study the distribution of fluorescently labelled peptides, antibodies and ASO's

Scan the QR code to download the poste

